<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212638</url>
  </required_header>
  <id_info>
    <org_study_id>14934</org_study_id>
    <secondary_id>I4V-MC-JAGU</secondary_id>
    <nct_id>NCT03212638</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib in Healthy Participants</brief_title>
  <official_title>A Bioequivalence and Food Effect Study in Healthy Subjects Comparing Baricitinib Suspension and Commercial Tablet Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine:

        -  If there are any differences in the amount of baricitinib in the blood/body when taken
           in two different forms.

        -  How a high-fat, high-calorie meal affects the amount of baricitinib in the blood/body.

        -  The safety and tolerability of baricitinib.

      The study has two parts. Individuals will participate in only one part.

      Participants will be admitted to the clinical research unit (CRU) and will be discharged from
      the CRU following the completion of 3 overnight stays.

      Each part of this study will last from 8-10 days, not including screening. Follow-up will
      occur 7 to 14 days after the last dose of baricitinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Actual">November 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib</measure>
    <time_frame>Predose through 48 hours after administration of study drug in each period</time_frame>
    <description>PK: Cmax of Baricitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Time Zero to the Last Time Point with a Measurable Concentration (AUC[0-tlast]) of Baricitinib</measure>
    <time_frame>Predose through 48 hours after administration of study drug in each period</time_frame>
    <description>PK: AUC(0-tlast) of Baricitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration versus Time Curve from Time Zero to Infinity (AUC[0-∞]) of Baricitinib</measure>
    <time_frame>Predose through 48 hours after administration of study drug in each period</time_frame>
    <description>PK: AUC(0-∞) of Baricitinib</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Baricitinib T1 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib suspension administered orally without water when fasting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib T2 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib suspension administered orally with water when fasting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib R (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib tablet administered orally with water when fasting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib TF Fasted (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib suspension test formulation (TF) administered when fasting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib TF Fed (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib suspension TF administered after a meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib suspension</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Baricitinib T1 (Part A)</arm_group_label>
    <arm_group_label>Baricitinib T2 (Part A)</arm_group_label>
    <arm_group_label>Baricitinib TF Fasted (Part B)</arm_group_label>
    <arm_group_label>Baricitinib TF Fed (Part B)</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib tablet</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Baricitinib R (Part A)</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  Women not of child-bearing potential

          -  Have a body mass index (BMI) of 18.5 to 29.9 kilograms per meter squared (kg/m²)
             inclusive, at screening

        Exclusion Criteria:

          -  Have received live vaccine(s) within 3 months of screening, or intend to during the
             study

          -  Have a current or recent history (less than [&lt;] 30 days prior to screening and/or &lt;45
             days prior to Day -1 in Period 1) of a clinically significant bacterial, fungal
             parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

